New Clinical Trial Aims to Target Measurable Residual Disease in Acute Myeloid Leukemia

Strategic Insights -

Clinical trial investigators are racing to develop new treatments for Acute Myeloid Leukemia (AML), one of the most aggressive forms of blood cancer. Jacqueline Garcia, MD has recently listed an interventional clinical trial, Phase 1, 2, to Study Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax. The trial aims to test the safety and efficacy of a new combination therapy using three agents: azacitidine, venetoclax, and tagraxofusp.

Key Takeaways:

  • The trial, led by Jacqueline Garcia, MD, is a Phase 1/2 study that aims to test the safety and efficacy of a new combination therapy for AML.
  • The study involves 31 participants from the USA and is not yet open for recruiting.
  • The combination therapy includes tagraxofusp (a type of CD123-directed cytotoxin), azacitidine (a type of standard of care cytidine nucleoside analog), and venetoclax (a type of standard of care BCL-2 inhibitor).
  • The study's purpose is to determine if the combination therapy can safely help to control residual AML and prevent disease recurrence.
  • The research study is a collaboration between Jacqueline Garcia, MD, Stemline Therapeutics, Inc., and Break Through Cancer Foundation.

Statistics:

  • 31: The number of participants in the study.
  • USA: The country from which participants will be recruited.
  • 3: The number of study drugs involved in the combination therapy.
  • Tagraxofusp: A type of CD123-directed cytotoxin being used in the study.
  • Azacitidine and Venetoclax: Types of standard of care cytidine nucleoside analog and BCL-2 inhibitor, respectively.

Sources:

  • ClinicalTrials.gov
  • Stemline Therapeutics, Inc.
  • Break Through Cancer Foundation